Búsqueda | Biblioteca Virtual en Salud

1.

[The medical curriculum need not take the religious beliefs and cultural background of the students into consideration]. / De medische opleiding hoeft geen rekening te houden met de geloofsovertuiging en cultuuropvattingen van studenten.

Splinter, T A W.

Ned Tijdschr Geneeskd ; 150(49): 2721, 2006 Dec 09.

Artículo en Neerlandesa | MEDLINE | ID: mdl-17194012

2.

Decarboxylated-S-adenosylmethionine excretion: a biochemical marker of ornithine decarboxylase inhibition by alpha-difluoromethylornithine.

Haegele, K D; Splinter, T A; Romijn, J C; Schechter, P J; Sjoerdsma, A.

Cancer Res ; 47(3): 890-5, 1987 Feb 01.

Artículo en Inglés | MEDLINE | ID: mdl-3100028

3.

Activated ras genes in human seminoma: evidence for tumor heterogeneity.

Mulder, M P; Keijzer, W; Verkerk, A; Boot, A J; Prins, M E; Splinter, T A; Bos, J L.

Oncogene ; 4(11): 1345-51, 1989 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-2682461

4.

Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

Splinter, T A; Sahmoud, T; Festen, J; van Zandwijk, N; Sörenson, S; Clerico, M; Burghouts, J; Dautzenberg, B; Kho, G S; Kirkpatrick, A; Giaccone, G.

J Clin Oncol ; 14(1): 127-34, 1996 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-8558187

5.

Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.

Tjan-Heijnen, V C; Biesma, B; Festen, J; Splinter, T A; Cox, A; Wagener, D J; Postmus, P E.

J Clin Oncol ; 16(8): 2708-14, 1998 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9704721

6.

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

Giaccone, G; Splinter, T A; Debruyne, C; Kho, G S; Lianes, P; van Zandwijk, N; Pennucci, M C; Scagliotti, G; van Meerbeeck, J; van Hoesel, Q; Curran, D; Sahmoud, T; Postmus, P E.

J Clin Oncol ; 16(6): 2133-41, 1998 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-9626213

7.

Chemotherapy in advanced non-small cell lung cancer.

Splinter, T A.

Eur J Cancer ; 26(10): 1093-9, 1990.

Artículo en Inglés | MEDLINE | ID: mdl-2177347

8.

Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group.

Postmus, P E; Smit, E F; Kirkpatrick, A; Splinter, T A.

Eur J Cancer ; 29A(2): 204-7, 1993.

Artículo en Inglés | MEDLINE | ID: mdl-8380697

9.

Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer.

van der Gaast, A; Kok, T C; Kho, G S; Blijenberg, B G; Splinter, T A.

Eur J Cancer ; 31A(11): 1790-3, 1995 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-8541102

10.

Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group.

Kok, T C; van der Gaast, A; Splinter, T A; Tilanus, H W.

Eur J Cancer ; 27(9): 1112-4, 1991.

Artículo en Inglés | MEDLINE | ID: mdl-1835618

11.

Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.

van der Gaast, A; Hulshof, C; Kok, T C; van Loon, E; Splinter, T A.

Eur J Cancer ; 29A(6): 870-3, 1993.

Artículo en Inglés | MEDLINE | ID: mdl-8484981

12.

A phase I study of local treatment of liver metastases with recombinant tumour necrosis factor.

van der Schelling, G P; IJzermans, J N; Kok, T C; Scheringa, M; Marquet, R L; Splinter, T A; Jeekel, J.

Eur J Cancer ; 28A(6-7): 1073-8, 1992.

Artículo en Inglés | MEDLINE | ID: mdl-1627378

13.

Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.

Postmus, P E; Scagliotti, G; Groen, H J; Gozzelino, F; Burghouts, J T; Curran, D; Sahmoud, T; Kirkpatrick, A; Giaccone, G; Splinter, T A.

Eur J Cancer ; 32A(9): 1498-503, 1996 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-8911108

14.

Genitourinary group phase II study of chemotherapy in stage T3-4 N0-X M0 transitional cell cancer of the bladder: prognostic factor analysis.

Splinter, T A; Pavone-Macaluso, M; Jacqmin, D; Roberts, J T; Carpentier, P; de Pauw, M; Sahmoud, T.

Eur J Cancer ; 32A(7): 1129-34, 1996 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-8758242

15.

Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer.

van der Gaast, A; Schoenmakers, C H; Kok, T C; Blijenberg, B G; Hop, W C; Splinter, T A.

Eur J Cancer ; 30A(12): 1783-6, 1994.

Artículo en Inglés | MEDLINE | ID: mdl-7880606

16.

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.

Polee, M B; Verweij, J; Siersema, P D; Tilanus, H W; Splinter, T A W; Stoter, G; Van der Gaast, A.

Eur J Cancer ; 38(11): 1495-500, 2002 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-12110496

17.

Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group.

Postmus, P E; Splinter, T A; Palmen, F M; Carney, D N; Festen, J; Burghouts, J T; Vendrik, C; Roozendaal, K; Planting, A S; Quoix, E.

Eur J Cancer ; 28(1): 96-100, 1992.

Artículo en Inglés | MEDLINE | ID: mdl-1314632

18.

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.

Sahmoud, T; Postmus, P E; van Pottelsberghe, C; Mattson, K; Tammilehto, L; Splinter, T A; Planting, A S; Sutedja, T; van Pawel, J; van Zandwijk, N; Baas, P; Roozendaal, K J; Schrijver, M; Kirkpatrick, A; Van Glabbeke, M; Ardizzoni, A; Giaccone, G.

Eur J Cancer ; 33(13): 2211-5, 1997 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-9470808

19.

Introduction to the treatment of lung cancer.

Splinter, T A.

Semin Oncol ; 24(4 Suppl 12): S12-1-S12-5, 1997 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9331110

20.

Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer.

Splinter, T A.

Semin Oncol ; 23(6 Suppl 16): 59-61, 1996 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-9007124

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

[The medical curriculum need not take the religious beliefs and cultural background of the students into consideration]. / De medische opleiding hoeft geen rekening te houden met de geloofsovertuiging en cultuuropvattingen van studenten.

Decarboxylated-S-adenosylmethionine excretion: a biochemical marker of ornithine decarboxylase inhibition by alpha-difluoromethylornithine.

Activated ras genes in human seminoma: evidence for tumor heterogeneity.

Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

Chemotherapy in advanced non-small cell lung cancer.

Testing the possible non-cross resistance of two equipotent combination chemotherapy regimens against small-cell lung cancer: a phase II study of the EORTC Lung Cancer Cooperative Group.

Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer.

Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group.

Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.

A phase I study of local treatment of liver metastases with recombinant tumour necrosis factor.

Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial.

Genitourinary group phase II study of chemotherapy in stage T3-4 N0-X M0 transitional cell cancer of the bladder: prognostic factor analysis.

Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer.

Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.

Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group.

Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.

Introduction to the treatment of lung cancer.

Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer.